N4 Pharma Plc

SRI Collaboration

Nuvec®

N4 Pharma Education

AIM Rule 26

Updates

Investors Home

Presentations

Regulatory news

Investors

Contact us

Partnership opportunities

Home

Senior leadership team

About Us

Leadership team

Nanogenics

Company

N4 101

ECP 105

Pipeline & partnerships

Open Sans

SRI’s Fox 3 MGS targeting peptide is being combined with N4 Pharma’s Nuvec® nanoparticle. It has been confirmed so far that the combined particle is only taken up into targeted cells and that there is a strong specific cellular knockdown of target genes. Data are currently being presented to major pharmaceutical companies for joint development and licensing.

SRI is an independent non-profit research institute based in Menlo Park, California. Its Molecular Guidance System (MGS) technology is designed to overcome cellular barriers that prevent intracellular delivery of large molecule biotherapeutics. The system uses proprietary technology that enables the delivery of macromolecular payloads to the target cell and then on to subcellular locations within those cells. SRI has demonstrated that MGS technology can deliver more than a dozen types of payloads – from functional enzymes, antibodies, and nucleic acids (including siRNA, ASOs, and DNA) to liposomes and nanoparticles – to targeted, intracellular molecular-target locations previously considered unreachable and therefore untreatable.

N4 Pharma is actively seeking partners for current assets/programmes and discovery/development programmes. Please get in touch to set up a meeting.